August 27, 2012

Genzyme Provides Update on U.S. LEMTRADA™(*) Filing

 

Genzyme Provides Update on U.S. LEMTRADA™(*) Filing

Paris, France – August 27, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced that Genzyme has received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of LEMTRADA™ (alemtuzumab) as a treatment for relapsing multiple sclerosis.